(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 February 2012 (23.02.2012)

PCT

(10) International Publication Number
WO 2012/022814 A1

(51) **International Patent Classification**:
C07K 16/32 (2006.01) ***A61P 35/00*** (2006.01)
A61K 39/395 (2006.01)

(21) **International Application Number**:
PCT/EP2011/064407

(22) **International Filing Date**:
22 August 2011 (22.08.2011)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/375,408 20 August 2010 (20.08.2010) US

(71) **Applicant** *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **ELIS, Winfried** [DE/DE]; MORPHOSYS AG, Lena-Christ-Strasse 48, 82152 Planegg (DE). **ETTENBERG, Seth** [US/US]; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **GARNER, Andrew Paul** [GB/US]; Novartis Institutes for BioMedical Research, Inc., 250 Massachussetts Avenue, Cambridge, Massachusetts 02139 (US). **HAUBST, Nicole** [DE/DE]; MORPHOSYS AG, Lena-Christ-Strasse 48, 82152 Planegg (DE). **KUNZ, Christian Carsten Silvester** [DE/DE]; MORPHOSYS AG, Lena-Christ-Strasse 48, 82152 Planegg (DE). **REISINGER SPRAGUE, Elizabeth Anne** [US/US]; Novartis Institutes for BioMedical Research, Inc., 250 Massachussetts Avenue, Cambridge, Massachusetts 02139 (US).

(74) **Agent**: **VON SPRECHER, Georg**; NOVARTIS PHARMA AG, Patent Department, CH-4002 Basel (CH).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2012/022814 A1

(54) **Title**: ANTIBODIES FOR EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)

(57) **Abstract**: The present invention relates to antibodies or fragments thereof that target a conformational epitope of a HER receptor. In particular, the invention relates to antibodies or fragments thereof that target a conformational epitope of HER3 receptor and compositions and methods of use thereof.